Tag - KDMN

Markets

Cantor starts Equillium at OW, PT $14

Cantor Fitzgerald launched coverage of Equillium (NASADQ:EQ) with an “overweight” rating and $14 price target. The stock closed at $5.40 on Sept. 14. Equillium is developing itolizumab, its novel CD6 targeted monoclonal...

September 15, 2021

Developments

Kadmon reports positive topline results from pivotal GvHD trial

Kadmon Holdings (NYSE:KDMN) reported positive topline results from its pivotal trial of KD025 (belumosudil) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of...

May 21, 2020

Developments

Kadmon KD025 meets primary endpoint at interim analysis of pivotal GvHD trial

Kadmon Holdings’ (NYSE:KDMN) KD025 met its primary endpoint at an interim analysis of its registrational chronic graft-versus-host disease (cGVHD) trial. cGvHD is a deadly complication of hematopoietic stem cell...

November 12, 2019

Developments

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...

September 18, 2019

Developments

Kadmon Holdings completes enrollment for registrational GvHD trial

Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell...

August 14, 2019

Tag - KDMN

Cantor starts Equillium at OW, PT $14

Kadmon reports positive topline results from pivotal GvHD trial

Kadmon KD025 meets primary endpoint at interim analysis of pivotal GvHD trial

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

Kadmon Holdings completes enrollment for registrational GvHD trial

General

More